Risk factors for subclinical inflammation in children with Familial Mediterranean fever

详细信息    查看全文

• 作者：Meral Torun Bayram ; Tufan ?ankaya ; El?in Bora ; Salih Kavuk?u…
• 关键词：Familial Mediterranean fever ; Risk factors ; Subclinical inflammation
• 刊名：Rheumatology International
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：35
• 期：8
• 页码：1393-1398
• 全文大小：409 KB
• 参考文献：1.Ozturk C, Hal?c?o?lu O, Coker I, Gulez N, Sut?uo?lu S, Karaca N, Aksu G, Kutukcular N (2012) Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol 31:493-01PubMed View Article
  2.Oz?akar ZB, Yal?inkaya F, Yüksel S, Acar B, G?kmen D, Ekim M (2006) Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 25(2):149-52PubMed View Article
  3.The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797-07View Article
  4.Padeh S, Berkun Y (2007) Auto-inflammatory fever syndromes. Rheum Dis Clin N Am 33:585-23View Article
  5.Saat?i U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, Arslan S (1997) Familial Mediterranean Fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:619-23PubMed View Article
  6.Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351:659-64PubMed View Article
  7.Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415PubMed View Article
  8.Korkmaz C, Ozdogan H, Kasap?opur O, Yazici H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61(1):79-1PubMed Central PubMed View Article
  9.Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1876-885View Article
  10.Majeed HA, Al-Qudah AK, Qubain H, Shahin HM (2000) The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 30(2):138-43PubMed View Article
  11.Tchernitchko D, Legendre M, Delahaye A, Cazeneuve C, Niel F, Goossens M, Amselem S, Girodon E (2003) Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. Clin Chem 49:1942-945PubMed View Article
  12.?akmak E, Ece A, Kelek?i S, Yolba? ?, Güne? A, ?en V (2013) Comparison of acute phase response during attack and attack-free period in children with Familial Mediterranean Fever. J Clin Exp Invest 4:213-18View Article
  13.Lachmann HJ, Sengül B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M, Hawkins PN (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746-50View Article
  14.Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, Bassoy Y, Yilmaz E (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509-14PubMed
  15.Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105-12PubMed View Article
  16.Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A (2005) Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 35(1):57-4PubMed View Article
  17.Gershoni-Baruch R, Brik R, Lidar M, Shinawi M, Livneh A (2003) Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 30(2):308-12PubMed
  18.Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149-155PubMed View Article
  19.Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, Shainberg B, Livneh A (2007) A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 37(3):182-88PubMed View Article
  20.Sar? I, Birlik M, Ka?ifo?lu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheum 1:21-3View Article
  21.Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 291(18):934-37PubMed View Article
  22.Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001-005PubMed View Article
  23.Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, Pras M (1996) The changing face of familial Mediterranean fever. Semin Arthritis Rheum 26(3):612-27PubMed View Article
  24.Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S, Pras M, Livneh A (2001) Common MEFV mutations
• 作者单位：Meral Torun Bayram (1)
  Tufan ?ankaya (2)
  El?in Bora (2)
  Salih Kavuk?u (1)
  Ayfer ülgenalp (1)
  Alper Soylu (1)
  Mehmet Türkmen (1)
  
  1. Department of Pediatric Nephrology, Dokuz Eylul University Medical Faculty, Izmir, Turkey
  2. Department of Pediatric Genetics, Medical Faculty, Dokuz Eylül University, Izmir, Turkey
  
• 刊物主题：Rheumatology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1437-160X

文摘

Familial Mediterranean fever (FMF) is the most common autosomal recessive inherited inflammatory disease characterized by attacks of painful inflammation. Some patients with FMF have subclinical inflammation persisting between the attacks. We aimed to identify the demographic, clinical and genetic risk factors for subclinical inflammation in children with FMF. The medical records of the children with FMF were evaluated retrospectively for acute-phase response along with gender, age at the onset of symptoms and at the time of diagnosis, clinical signs and symptoms, the presence of amyloidosis and MEFV genotype. Patients with persistently elevated acute-phase response between the attacks were considered to have subclinical inflammation. Patients with or without subclinical inflammation (Group 1 and Group 2, respectively) were compared for the parameters defined above. Independent risk factors for subclinical inflammation were identified by multivariate logistic regression analysis. There were 105 children (male/female: 52/53) who were compliant on colchicine treatment. Subclinical inflammation was detected in 22 (20?%) patients. Group 1 had significantly higher rate of myalgia, arthritis/arthralgia, erysipelas like erythema, amyloidosis, protracted febrile myalgia and M694V mutation compared with Group 2. However, only the presence of myalgia and erysipelas like erythema were found to be independent risk factors for subclinical inflammation (OR 9.8 and 5.9, respectively). Children with FMF who have myalgia and erysipelas like erythema during the attacks are particularly at risk of ongoing inflammation and should be closely monitored for subclinical inflammation even during attack-free periods.